Vamorolone 4% suspension for oral dosing ( DrugBank: Vamorolone )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 97 | Ulcerative colitis | 1 |
97. Ulcerative colitis
Clinical trials : 2,527 / Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04348890 (ClinicalTrials.gov) | September 1, 2020 | 13/4/2020 | Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis | A Phase I/II Open-Label, Proof-of-Concept Study of Vamorolone in Children and Adolescents With Mild-Moderately Active Ulcerative Colitis | Pediatric Ulcerative Colitis | Drug: Vamorolone 4% suspension for oral dosing | ReveraGen BioPharma, Inc. | NULL | Withdrawn | 4 Years | 17 Years | All | 0 | Phase 1/Phase 2 | NULL |